Specifics of arterial hypertension in elderly patients

Czech version

Authors: Peter Mikus
Authors‘ workplace: Klinika geriatrie LF SZU a UNB, Nemocnica Ružinov, Bratislava
Published in: Diab Obez 2025; 25(2): 109-115
Category: Reviews

Overview

Arterial hypertension is common in the elderly. It is due to the arterial stiffness, neurohormonal and autonomic dysregulation, the ageing kidney and unhealthy lifestyle. A correct diagnosis of hypertension is important. There are wide evidence based possibilities for treatment of hypertension in elderly patients.

Keywords:

diagnosis – treatment – benefit – elderly patients –hypertension

Sources

Mancia D, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281–1357. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjh.0000431740.32696.cc>.

Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41(12): 1874–2071. Dostupné z DOI: <http://dx10.1097/HJH.0000000000003480>. Erratum in: J Hypertens 2024; 42(1): 194. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000003621>.

Krajčík Š, Dúbrava M, Bartošovič I et al. Geriatria. 2. doplnené a prepracované vydanie. Herba: Bratislava 2022. ISBN 978–80 -⁠ 8229–020–5.

McEvoy JW, McCarthy CP, Bruno RM et al. [ESC Scientific Document Group]. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024; 45(38): 3912–4018. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehae178>. Erratum in: Eur Heart J 2025; 46(14): 1300. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaf031>.

Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355(9207): 865–872. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140–6736(99)07330–4>. Erratum in: Lancet 2001; 357(9257): 724.

Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350(9080): 757–764. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140–6736(97)05381–6>.

[SHEP Cooperative Research Group]. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265(24): 3255–3264.

Beckettt NS, Peters R, Fletcher RP et al. Treatment of hypertension in patients 80 years of age and older. N Eng J Med 2008; 358(18): 1887–1898. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0801369>.

Wright JT jr, Williamson JD, Whelton PK et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373(22): 2103–16. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1511939>. Erratum in: N Engl J Med 2017; 377(25): 2506. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMx170008>.

Williamson JD, Supiano MA, Applegate WB et al. [SPRINT Research Group]. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥ 75 Years: A Randomized Clinical Trial. JAMA 2016; 315(24): 2673–2682. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.7050>.

Hegyi L, Krajčík Š. Geriatria pre praktického lekára. 3rd ed. Herba: Bratislava 2015. ISBN 9788089631315.

Wu J, Yin X, Ji W et al. Hypertension and diabetes on cognitive impairment: a case-control study in China. Alzheimers Res Ther 2025; 17(1): 120. Dostupné z DOI: <http://dx.doi.org/10.1186/s13195–025–01761–3>. Erratum in: Alzheimers Res Ther 2025; 17(1): 181. Dostupné z DOI: <http://dx.doi.org/10.1186/s13195–025–01824–5>.

Wang N, Chalmers J, Harris K et al. Combination blood pressure lowering therapy in patients with type 2 diabetes: messages from the ADVANCE trial. J Hypertens 2024; 42(12): 2055–2064. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000003855>.

Zhang Z, Chen H, Chen L et al. Blood pressure and the risk of diabetes: A longitudinal observational study based on Chinese individuals. J Diabetes Investig 2025; 16(6): 1081–1090. Dostupné z DOI: <http://dx.doi.org/10.1111/jdi.70029>.

Bi Y, Li M, Liu Y et al. [BPROAD Research Group]. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med 2025; 392(12): 1155–1167. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2412006>.

Yang C, Hu Z, Sa R et al. Reducing the Risk of Developing Diabetes: The Role of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors in Patients With Hypertension Combined Prediabetes. J Clin Hypertens (Greenwich) 2025; 27(5): e70025. Dostupné z DOI: <http://dx.doi.org/10.1111/jch.70025>.

Suzuki Y, Kaneko H, Okada A et al. Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors. Hypertens Res 2024; 47(7): 1789–1796. Dostupné z DOI: <http://dx.doi.org/10.1038/s41440–024–01649-z>.